Episodes 1-15 of 56
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Project Oncology®HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Differential Diagnosis of Indolent Systemic Mastocytosis
MinuteCE®Differential Diagnosis of Indolent Systemic Mastocytosis
Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm
MinuteCE®Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm
Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia
MinuteCE®Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia
Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor
MinuteCE®Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor
Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies
MinuteCE®Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies
Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy
MinuteCE®Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy
Emerging data with potentially guideline-changing implications in CLL/SLL and MCL
MinuteCE®Emerging data with potentially guideline-changing implications in CLL/SLL and MCL
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
MinuteCE®Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma